Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,444 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pharmacodynamics Clear all

Conditions: Overweight, Diabetes Mellitus Type 2 in Obese
Interventions: P11187, Placebo; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Feeding and Eating Disorders
Interventions: GT-001; Drug
Lead sponsor: Gila Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tustin, California

Conditions: Glioblastoma or Malignant Glioma
Interventions: AMG 596, AMG 404; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Cocaine Use, Pharmacokinetics
Interventions: cocaine, quinine, acetazolamide; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: VEGFR/PDGFR dual kinase inhibitor X-82, docetaxel, fluorine F 18 fluorothymidine, positron emission tomography/computed tomography, pharmacological study, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetes Mellitus
Interventions: Insulin; Drug
Lead sponsor: QDose Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Participants
Interventions: ACP-196, Itraconazole; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Leukemia
Interventions: Nelarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Non-hematologic Malignancies
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more

Conditions: Solid Tumor
Interventions: SAIL66; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Gilbert, Arizona • Augusta, Georgia • Charleston, South Carolina + 2 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: TEPEZZA, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more

Conditions: Advanced Malignancies
Interventions: Patupilone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced or Metastatic Solid Tumors
Interventions: TAK-188; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 15
States / cities: Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Multiple Myeloma
Interventions: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Solid Tumours
Interventions: GSK525762, Abiraterone, Enzalutamide, Prednisone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 9
States / cities: Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 6 more

Conditions: 21-hydroxylase Deficiency
Interventions: Abiraterone acetate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: LY3437943, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Anaheim, California • Miami, Florida • Lenexa, Kansas + 1 more

Conditions: Healthy Elderly
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: South Miami, Florida

Conditions: Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
Interventions: FORE8394; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 10 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 13
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 9 more

Conditions: Pulmonary Arterial Hypertension
Interventions: RVT-1201, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more

Conditions: Colitis, Ulcerative
Interventions: GSK2982772, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Advanced Solid Tumors
Interventions: BMS-986449, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more

Search by objective public record fields.

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Interactions Between Intravenous Cocaine and Acetazolamide or Quinine

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

GSK2982772 Study in Subjects With Ulcerative Colitis

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors